Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil Considers Easier Path For Compulsory Licensing

President Is Unlikely To Sign Off Bill

Executive Summary

A bill amending Brazilian patent law to make compulsory licensing easier has passed the senate but still must be signed off by president Jair Bolsonaro.

You may also be interested in...



Brazil Waters Down Compulsory Licensing Law

Companies in Brazil will not have to provide know-how and other detailed information on patents that are subject to compulsory licenses, although other provisions of a law passed last year to ease the compulsory licensing process remain in place.

EU Backs Compulsory Licensing & Production Boost For COVID-19 Vaccines

The European Commission is to present the World Health Organization with a set of proposals to tackle the barriers to the global rollout of COVID-19 vaccines. They include allowing the issue of compulsory licenses without consulting the rights holder, encouraging vaccine companies to expand production through licensing deals and contract manufacturing, and eliminating vaccine export restrictions.

Brazilian HTA To Adopt Cost-Effectiveness Thresholds

Brazil’s health technology assessment institute is to incorporate cost-effectiveness thresholds into its decision making.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel